USC School of Pharmacy Revenue and Competitors

Location

N/A

Total Funding

Education

Industry

Estimated Revenue & Valuation

  • USC School of Pharmacy's estimated annual revenue is currently $97.2M per year.(i)
  • USC School of Pharmacy's estimated revenue per employee is $225,000

Employee Data

  • USC School of Pharmacy has 432 Employees.(i)

USC School of Pharmacy's People

NameTitleEmail/Phone
1
executive director community pharmacy practiceReveal Email/Phone
2
Graduate Research AssociateReveal Email/Phone
3
Associate Professor Clinical Pharmacy at the USC School PharmacyReveal Email/Phone
4
Administrative AssistantReveal Email/Phone
5
Video EditorReveal Email/Phone
6
Pharmacy StudentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11047.7M43840N/AN/AN/A
#2
$844.7M3352N/AN/AN/A
#3
$476.5M1891N/AN/AN/A
#4
$75M196N/AN/AN/A
Add Company

What Is USC School of Pharmacy?

The highest-ranked private pharmacy school, USC School of Pharmacy is the only school in the nation that spans the entire spectrum of pharmaceutical development and clinical care.

keywords:N/A

N/A

Total Funding

432

Number of Employees

$97.2M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

USC School of Pharmacy News

2022-04-06 - Keck Medicine of USC opens new, state-of-the-art oncology ...

The National Cancer Institute (NCI) has designated USC Norris as one of ... The pharmacy will then use the lab work to develop and customize...

2022-03-30 - USC gives honorary degrees to Japanese American students

In 2012, USC announced it would award honorary degrees to the ... in his first year at USC's pharmacy school when he joined the military.

2022-03-30 - Keck Medicine of USC announces collaboration with The ...

On March 31, Keck Medicine of USC announced a strategic collaboration with The TransLatin Coalition, the largest ... USC School of Pharmacy

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M4320%N/A
#2
$146.5M43410%N/A
#3
$109M43469%N/A
#4
$234.8M4361%$1M
#5
$35M436N/AN/A